Linked Life Data

8848413

Source:http://linkedlifedata.com/resource/pubmed/id/8848413

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1996-10-22
pubmed:abstractText
The study was aimed to assess the efficacy of busulphan treatment in patients with polycythemia rubra vera (PRV). The group of 74 patients (mean age 60 years, range: 40-81) was studied, including 38 females, 36 males. The remission was achieved in all cases; the mean time of remission was 33 months (range 3-200), the mean busulphan dose necessary to reach the first PRV remission was 266 mg (range: 76-600). The associations between hemoglobin level, white blood cells, neurocytes, platelet counts at diagnosis and the mean cumulative busulphan dose necessary to obtain the first PRV remission as well as between above parameters and the mean duration of the first PRV remission was estimated. The mean duration of the first PRV remission was significantly (P < 0.03) longer in patients with neurocyte count below 9.6 G/l (9.6 x 10(3)/mm3) as compared to those with higher levels; except it, no relationship were noticed between above parameters. The results of the study confirmed that busulphan is an effective and safe drug for patients with PRV.
pubmed:language
pol
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0032-3772
pubmed:author
pubmed:issnType
Print
pubmed:volume
95
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
453-8
pubmed:dateRevised
2010-4-1
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
[Evaluation of treatment results in patients with polycythemia rubra vera].
pubmed:affiliation
Klinika Hematologii Instytutu Chorób Wewnetrznych Akademii Medycznej w Gda?sku.
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract